Structural basis for the recognition of the S2, S5-phosphorylated RNA polymerase II CTD by the mRNA anti-terminator protein hSCAF4. Read more about Structural basis for the recognition of the S2, S5-phosphorylated RNA polymerase II CTD by the mRNA anti-terminator protein hSCAF4.
Discovery of Novel BRD4 Ligand Scaffolds by Automated Navigation of the Fragment Chemical Space. Read more about Discovery of Novel BRD4 Ligand Scaffolds by Automated Navigation of the Fragment Chemical Space.
The Transcriptional Repressor Orphan Nuclear Receptor TLX Is Responsive to Xanthines. Read more about The Transcriptional Repressor Orphan Nuclear Receptor TLX Is Responsive to Xanthines.
Prediction and Validation of a Protein's Free Energy Surface Using Hydrogen Exchange and (Importantly) Its Denaturant Dependence. Read more about Prediction and Validation of a Protein's Free Energy Surface Using Hydrogen Exchange and (Importantly) Its Denaturant Dependence.
Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells. Read more about Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.
Histone lysine methacrylation is a dynamic post-translational modification regulated by HAT1 and SIRT2. Read more about Histone lysine methacrylation is a dynamic post-translational modification regulated by HAT1 and SIRT2.
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Read more about TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Design of a Potent TLX Agonist by Rational Fragment Fusion. Read more about Design of a Potent TLX Agonist by Rational Fragment Fusion.
Structural Aspects of LIMK Regulation and Pharmacology. Read more about Structural Aspects of LIMK Regulation and Pharmacology.
Autoantibodies against Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from an Australian Single-Center Cohort. Read more about Autoantibodies against Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from an Australian Single-Center Cohort.
